Dr. Luke on Immunotherapy Diagnostics in Melanoma

Jason Luke, MD
Published: Thursday, Oct 20, 2016



Jason Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the various methods involved in immunotherapy diagnostics in the treatment landscape of melanoma.

One such method is PD-L1 immunohistochemistry. However, Luke notes, even patients who are technically negative for PD-L1 expression have been found to benefit more from these types of drugs than other agents.

Another method involves looking at the mutational load in the cancer. Some oncologists have found that, if tumors have a very high mutational rate in the cancer, the likelihood of response is very high, explains Luke.


Jason Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the various methods involved in immunotherapy diagnostics in the treatment landscape of melanoma.

One such method is PD-L1 immunohistochemistry. However, Luke notes, even patients who are technically negative for PD-L1 expression have been found to benefit more from these types of drugs than other agents.

Another method involves looking at the mutational load in the cancer. Some oncologists have found that, if tumors have a very high mutational rate in the cancer, the likelihood of response is very high, explains Luke.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x